We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Sensus Healthcare (SRTS) Moves 19.9% Higher: Will This Strength Last?
Read MoreHide Full Article
Sensus Healthcare, Inc. (SRTS - Free Report) shares rallied 19.9% in the last trading session to close at $8.24. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 3.2% loss over the past four weeks.
Sensus Healthcare recorded a strong price rise on investors’ optimism surrounding the company’s impending fourth quarter and full year 2024 financial results, which is slated to release on Feb. 5. The Zacks Consensus Estimate for 2024 revenue suggests a growth of 58.1%. The company’s earnings is expected to grow to 41 cents per share compared with the 2023 figure.
This company is expected to post quarterly earnings of $0.10 per share in its upcoming report, which represents a year-over-year change of -61.5%. Revenues are expected to be $9.86 million, down 21.6% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Sensus Healthcare, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on SRTS going forward to see if this recent jump can turn into more strength down the road.
Sensus Healthcare is part of the Zacks Medical - Instruments industry. Artivion (AORT - Free Report) , another stock in the same industry, closed the last trading session 1.3% lower at $30.96. AORT has returned 11.7% in the past month.
Artivion's consensus EPS estimate for the upcoming report has remained unchanged over the past month at $0.12. Compared to the company's year-ago EPS, this represents a change of +9.1%. Artivion currently boasts a Zacks Rank of #3 (Hold).
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Sensus Healthcare (SRTS) Moves 19.9% Higher: Will This Strength Last?
Sensus Healthcare, Inc. (SRTS - Free Report) shares rallied 19.9% in the last trading session to close at $8.24. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 3.2% loss over the past four weeks.
Sensus Healthcare recorded a strong price rise on investors’ optimism surrounding the company’s impending fourth quarter and full year 2024 financial results, which is slated to release on Feb. 5. The Zacks Consensus Estimate for 2024 revenue suggests a growth of 58.1%. The company’s earnings is expected to grow to 41 cents per share compared with the 2023 figure.
This company is expected to post quarterly earnings of $0.10 per share in its upcoming report, which represents a year-over-year change of -61.5%. Revenues are expected to be $9.86 million, down 21.6% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Sensus Healthcare, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on SRTS going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Sensus Healthcare is part of the Zacks Medical - Instruments industry. Artivion (AORT - Free Report) , another stock in the same industry, closed the last trading session 1.3% lower at $30.96. AORT has returned 11.7% in the past month.
Artivion's consensus EPS estimate for the upcoming report has remained unchanged over the past month at $0.12. Compared to the company's year-ago EPS, this represents a change of +9.1%. Artivion currently boasts a Zacks Rank of #3 (Hold).